{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T23:17:30Z","timestamp":1768519050059,"version":"3.49.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.berh.2021.101691","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:59:23Z","timestamp":1621385963000},"page":"101691","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical and molecular significance of genetic loci associated with psoriatic arthritis"],"prefix":"10.1016","volume":"35","author":[{"given":"Darren D.","family":"O'Rielly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Proton","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2021.101691_bib1","series-title":"The family history\u2014more important than ever","author":"Guttmacher","year":"2004"},{"key":"10.1016\/j.berh.2021.101691_bib2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/ard.32.3.181","article-title":"Familial occurrence of psoriatic arthritis","volume":"32","author":"Moll","year":"1973","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101691_bib3","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1136\/ard.2008.089367","article-title":"Familial aggregation of psoriatic arthritis","volume":"68","author":"Chandran","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101691_bib4","first-page":"7","article-title":"A\u00a0population genetic study of psoriasis","volume":"186","author":"Swanbeck","year":"1994","journal-title":"Acta Derm Venereol Suppl"},{"key":"10.1016\/j.berh.2021.101691_bib5","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/rheumatology\/keh589","article-title":"Recurrence risk for psoriasis and psoriatic arthritis within sibships","volume":"44","author":"Myers","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2021.101691_bib6","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/ng.3941","article-title":"Concepts, estimation and interpretation of SNP-based heritability","volume":"49","author":"Yang","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.berh.2021.101691_bib7","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1038\/s41598-020-61981-5","article-title":"Quantifying differences in heritability among psoriatic arthritis (PsA), cutaneous psoriasis (PsC) and psoriasis vulgaris (PsV)","volume":"10","author":"Li","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.berh.2021.101691_bib8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/acr.23836","article-title":"Impact of having family history of psoriasis or psoriatic arthritis on psoriatic disease","volume":"72","author":"Solmaz","year":"2020","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2021.101691_bib9","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/art.33415","article-title":"HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype","volume":"64","author":"Winchester","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2021.101691_bib10","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1136\/annrheumdis-2012-201308","article-title":"Differential human leucocyte allele association between psoriasis and psoriatic arthritis: a family-based association study","volume":"71","author":"Eder","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101691_bib11","series-title":"Oxford textbook of psoriatic arthritis","first-page":"57","author":"Winchester","year":"2019"},{"key":"10.1016\/j.berh.2021.101691_bib12","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ajhg.2014.07.002","article-title":"Fine mapping major histocompatibility complex associations in psoriasis and its clinical subtypes","volume":"95","author":"Okada","year":"2014","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.berh.2021.101691_bib13","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1136\/annrheumdis-2014-207187","article-title":"PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus","volume":"74","author":"Bowes","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101691_bib14","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.ajhg.2015.10.019","article-title":"Genome-wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture","volume":"97","author":"Stuart","year":"2015","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.berh.2021.101691_bib15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1136\/annrheumdis-2014-205461","article-title":"Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype","volume":"75","author":"Haroon","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101691_bib16","first-page":"675","article-title":"Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model","volume":"22","author":"Gladman","year":"1995","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2021.101691_bib17","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.humimm.2013.07.014","article-title":"Human leukocyte antigen alleles and susceptibility to psoriatic arthritis","volume":"74","author":"Chandran","year":"2013","journal-title":"Hum Immunol"},{"key":"10.1016\/j.berh.2021.101691_bib18","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.3899\/jrheum.091311","article-title":"Folate pathway enzyme gene polymorphisms and the efficacy and toxicity of methotrexate in psoriatic arthritis","volume":"37","author":"Chandran","year":"2010","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2021.101691_bib19","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1007\/s10067-014-2807-8","article-title":"Distinct genetic profile in peripheral blood mononuclear cells of psoriatic arthritis patients treated with methotrexate and TNF-inhibitors","volume":"33","author":"Cuchacovich","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2021.101691_bib20","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics","volume":"58","author":"Menter","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.berh.2021.101691_bib21","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2021.101691_bib22","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/ard.2005.045658","article-title":"The infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiographic analyses after 1 year","volume":"65","author":"Kavanaugh","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101691_bib23","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2021.101691_bib24","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1038\/jid.2014.123","article-title":"TNF-alpha gene polymorphisms: association with disease susceptibility and response to anti-TNF-alpha treatment in psoriatic arthritis","volume":"134","author":"Murdaca","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.berh.2021.101691_bib25","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.2217\/pgs.13.146","article-title":"Association of TNF-alpha polymorphism with prediction of response to TNF blockers in spondyloarthritis and inflammatory bowel disease: a meta-analysis","volume":"14","author":"Tong","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.berh.2021.101691_bib26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/rheumatology\/kel175","article-title":"The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients","volume":"46","author":"Seitz","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2021.101691_bib27","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1111\/jdv.15431","article-title":"Polymorphisms associated with anti-TNF drugs response in patients with psoriasis and psoriatic arthritis","volume":"33","author":"Ovejero-Benito","year":"2019","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.berh.2021.101691_bib28","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2217\/pgs.16.20","article-title":"Pharmacogenomics of multifactorial diseases: a focus on psoriatic arthritis","volume":"17","author":"Cascella","year":"2016","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.berh.2021.101691_bib29","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jbspin.2012.02.003","article-title":"Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis","volume":"79","author":"Morales-Lara","year":"2012","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.berh.2021.101691_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194693","article-title":"Genetics in TNF-TNFR pathway: a complex network causing spondyloarthritis and conditioning response to anti-TNFalpha therapy","volume":"13","author":"Aita","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.berh.2021.101691_bib31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11926-015-0518-z","article-title":"Pharmacogenetics of treatment response in psoriatic arthritis","volume":"17","author":"Jani","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.berh.2021.101691_bib32","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3899\/jrheum.110980","article-title":"FCGR2A\/CD32A and FCGR3A\/CD16A variants and EULAR response to tumor necrosis factor-alpha blockers in psoriatic arthritis: a longitudinal study with 6 months of followup","volume":"39","author":"Ramirez","year":"2012","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2021.101691_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0110657","article-title":"Divergent gene activation in peripheral blood and tissues of patients with rheumatoid arthritis, psoriatic arthritis and psoriasis following infliximab therapy","volume":"9","author":"Rosenberg","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.berh.2021.101691_bib34","doi-asserted-by":"crossref","first-page":"21703","DOI":"10.1038\/s41598-020-78866-2","article-title":"Rho-GTPase pathways may differentiate treatment response to TNF-alpha and IL-17A inhibitors in psoriatic arthritis","volume":"10","author":"Rahmati","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.berh.2021.101691_bib35","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3899\/jrheum.190119","article-title":"The genetics of psoriasis and psoriatic arthritis","volume":"95","author":"O'Rielly","year":"2019","journal-title":"J\u00a0Rheumatol Suppl"},{"key":"10.1016\/j.berh.2021.101691_bib36","series-title":"Oxford textbook of psoriatic arthritis","author":"Stuart P","year":"2019"},{"key":"10.1016\/j.berh.2021.101691_bib37","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11926-020-0886-x","article-title":"Complexities in genetics of psoriatic arthritis","volume":"22","author":"Rahmati","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.berh.2021.101691_bib38","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/ng.311","article-title":"Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways","volume":"41","author":"Nair","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.berh.2021.101691_bib39","doi-asserted-by":"crossref","first-page":"6046","DOI":"10.1038\/ncomms7046","article-title":"Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis","volume":"6","author":"Bowes","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.berh.2021.101691_bib40","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/ng.693","article-title":"Genome-wide association analysis identifies three psoriasis susceptibility loci","volume":"42","author":"Stuart","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.berh.2021.101691_bib41","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/jid.2011.415","article-title":"Genome-wide meta-analysis of psoriatic arthritis identifies susceptibility locus at REL","volume":"132","author":"Ellinghaus","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.berh.2021.101691_bib42","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrrheum.2017.22","article-title":"Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases","volume":"13","author":"Croft","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2021.101691_bib43","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.1074\/jbc.275.7.4858","article-title":"Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts","volume":"275","author":"Azuma","year":"2000","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.berh.2021.101691_bib44","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10238-017-0475-0","article-title":"Expression of MIF and TNFA in psoriatic arthritis: relationship with Th1\/Th2\/Th17 cytokine profiles and clinical variables","volume":"18","author":"Bautista-Herrera","year":"2018","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.berh.2021.101691_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128262","article-title":"Gene expression profiling in peripheral blood cells and synovial membranes of patients with psoriatic arthritis","volume":"10","author":"Dolcino","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.berh.2021.101691_bib46","article-title":"Single nucleotide polymorphisms in the tumor necrosis factor-alpha gene promoter region alter the risk of psoriasis vulgaris and psoriatic arthritis: a meta-analysis","volume":"8","author":"Zhu","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.berh.2021.101691_bib47","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1136\/ard.2005.039164","article-title":"TNFalpha polymorphisms and risk of psoriatic arthritis","volume":"65","author":"Rahman","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101691_bib48","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/1744666X.2019.1564039","article-title":"Association of TNF, IL12, and IL23 gene polymorphisms and psoriatic arthritis: meta-analysis","volume":"15","author":"Loures","year":"2019","journal-title":"Expet Rev Clin Immunol"},{"key":"10.1016\/j.berh.2021.101691_bib49","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/1523-1747.ep12337469","article-title":"A\u00a0TNF-alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis","volume":"109","author":"Hohler","year":"1997","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.berh.2021.101691_bib50","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.0022-202X.2004.23556.x","article-title":"Association of TNF -238 and -308 promoter polymorphisms with psoriasis vulgaris and psoriatic arthritis but not with pustulosis palmoplantaris","volume":"124","author":"Mossner","year":"2005","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.berh.2021.101691_bib51","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.3899\/jrheum.131315","article-title":"Tumor necrosis factor-alpha promoter -308\/238 polymorphism association with less severe disease in ankylosing spondylitis is unrelated to serum TNF-alpha and does not predict TNF inhibitor response","volume":"41","author":"Nossent","year":"2014","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2021.101691_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000606","article-title":"Multiple Loci within the major histocompatibility complex confer risk of psoriasis","volume":"5","author":"Feng","year":"2009","journal-title":"PLoS Genet"},{"key":"10.1016\/j.berh.2021.101691_bib53","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/jir.2010.0126","article-title":"Systems biology of interferon responses","volume":"31","author":"Hertzog","year":"2011","journal-title":"J\u00a0Interferon Cytokine Res"},{"key":"10.1016\/j.berh.2021.101691_bib54","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1136\/annrheumdis-2016-210592","article-title":"A\u00a0rare coding allele in IFIH1 is protective for psoriatic arthritis","volume":"76","author":"Budu-Aggrey","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101691_bib55","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/nrrheum.2014.109","article-title":"PTPN22: the archetypal non-HLA autoimmunity gene","volume":"10","author":"Stanford","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2021.101691_bib56","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11926-013-0347-x","article-title":"Advances in the genetics of spondyloarthritis and clinical implications","volume":"15","author":"O'Rielly","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.berh.2021.101691_bib57","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1399-0039.2011.01670.x","article-title":"Differential major histocompatibility complex class I chain-related A allele associations with skin and joint manifestations of psoriatic disease","volume":"77","author":"Pollock","year":"2011","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.berh.2021.101691_bib58","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/tan.12126","article-title":"The functional MICA-129 polymorphism is associated with skin but not joint manifestations of psoriatic disease independently of HLA-B and HLA-C","volume":"82","author":"Pollock","year":"2013","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.berh.2021.101691_bib59","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1146\/annurev.immunol.23.021704.115526","article-title":"NK cell recognition","volume":"23","author":"Lanier","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.berh.2021.101691_bib60","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/annrheumdis-2014-206996","article-title":"Silencing or inhibition of endoplasmic reticulum aminopeptidase 1 (ERAP1) suppresses free heavy chain expression and Th17 responses in ankylosing spondylitis","volume":"75","author":"Chen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101691_bib61","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1002\/art.34538","article-title":"Inhibiting HLA-B27 homodimer-driven immune cell inflammation in spondylarthritis","volume":"64","author":"Payeli","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2021.101691_bib62","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/rheumatology\/ket296","article-title":"Killer-cell immunoglobulin-like receptor gene polymorphisms and susceptibility to psoriatic arthritis","volume":"53","author":"Chandran","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2021.101691_bib63","doi-asserted-by":"crossref","first-page":"26021","DOI":"10.1074\/jbc.M115.685909","article-title":"Structural basis for antigenic peptide recognition and processing by endoplasmic reticulum (ER) aminopeptidase 2","volume":"290","author":"Mpakali","year":"2015","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.berh.2021.101691_bib64","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/bjd.12142","article-title":"Investigation of 20 non-HLA (human leucocyte antigen) psoriasis susceptibility loci in Chinese patients with psoriatic arthritis and psoriasis vulgaris","volume":"168","author":"Yang","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.berh.2021.101691_bib65","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00005-016-0444-4","article-title":"ERAP1 and ERAP2 gene variations influence the risk of psoriatic arthritis in Romanian population","volume":"64","author":"Popa","year":"2016","journal-title":"Arch Immunol Ther Exp"},{"key":"10.1016\/j.berh.2021.101691_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1001157","article-title":"Balancing selection maintains a form of ERAP2 that undergoes nonsense-mediated decay and affects antigen presentation","volume":"6","author":"Andres","year":"2010","journal-title":"PLoS Genet"},{"key":"10.1016\/j.berh.2021.101691_bib67","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11010-011-1036-6","article-title":"IL-17 receptor and its functional significance in psoriatic arthritis","volume":"359","author":"Raychaudhuri","year":"2012","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.berh.2021.101691_bib68","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1186\/ar3781","article-title":"Functional role of IL-22 in psoriatic arthritis","volume":"14","author":"Mitra","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2021.101691_bib69","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/jid.2014.414","article-title":"Gene expression differences between psoriasis patients with and without inflammatory arthritis","volume":"135","author":"Pollock","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.berh.2021.101691_bib70","article-title":"Th17 gene expression in psoriatic arthritis synovial fluid and peripheral blood compared to osteoarthritis and cutaneous psoriasis","author":"Abji","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2021.101691_bib71","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1002\/art.39800","article-title":"Brief report: CXCL10 is a possible biomarker for the development of psoriatic arthritis among patients with psoriasis","volume":"68","author":"Abji","year":"2016","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2021.101691_bib72","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s13075-016-1196-6","article-title":"Differential gene and protein expression of chemokines and cytokines in synovial fluid of patients with arthritis","volume":"18","author":"Muntyanu","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2021.101691_bib73","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1038\/s41467-020-18513-6","article-title":"Single-cell sequencing reveals clonal expansions of pro-inflammatory synovial CD8 T cells expressing tissue-homing receptors in psoriatic arthritis","volume":"11","author":"Penkava","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.berh.2021.101691_bib74","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1038\/s41467-017-01771-2","article-title":"Unique transcriptome signatures and GM-CSF expression in lymphocytes from patients with spondyloarthritis","volume":"8","author":"Al-Mossawi","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.berh.2021.101691_bib75","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.clim.2008.01.019","article-title":"Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity","volume":"127","author":"Wong","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.berh.2021.101691_bib76","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.20041257","article-title":"IL-23 drives a pathogenic T cell population that induces autoimmune inflammation","volume":"201","author":"Langrish","year":"2005","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.berh.2021.101691_bib77","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jdermsci.2014.05.010","article-title":"Genetic variation at IL12B, IL23R and IL23A is associated with psoriasis severity, psoriatic arthritis and type 2 diabetes mellitus","volume":"75","author":"Eiris","year":"2014","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.berh.2021.101691_bib78","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1136\/annrheumdis-2016-209290","article-title":"Replication of a distinct psoriatic arthritis risk variant at the IL23R locus","volume":"75","author":"Budu-Aggrey","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101691_bib79","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.cyto.2013.03.015","article-title":"Protective effect of interleukin-23A (IL23A) haplotype variants on type 1A diabetes mellitus in a Brazilian population","volume":"62","author":"Costa","year":"2013","journal-title":"Cytokine"},{"key":"10.1016\/j.berh.2021.101691_bib80","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar2936","article-title":"Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors","volume":"12","author":"Adamopoulos","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2021.101691_bib81","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1136\/annrheumdis-2013-204782","article-title":"IL-17A gene transfer induces bone loss and epidermal hyperplasia associated with psoriatic arthritis","volume":"74","author":"Adamopoulos","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101691_bib82","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.berh.2021.101691_bib83","doi-asserted-by":"crossref","first-page":"951","DOI":"10.4049\/jimmunol.1003986","article-title":"IL-23 is critical for induction of arthritis, osteoclast formation, and maintenance of bone mass","volume":"187","author":"Adamopoulos","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.berh.2021.101691_bib84","first-page":"821","article-title":"Secukinumab improves physical function in subjects with plaque psoriasis and psoriatic arthritis: results from two randomized, phase 3 trials","volume":"14","author":"Gottlieb","year":"2015","journal-title":"J\u00a0Drugs Dermatol JDD"},{"key":"10.1016\/j.berh.2021.101691_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2021.101691_bib86","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2021.101691_bib87","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00296-011-2231-1","article-title":"Synovial fluid and serum levels of IL-17, IL-23, and CCL-20 in rheumatoid arthritis and psoriatic arthritis: a Tunisian cross-sectional study","volume":"33","author":"Mrabet","year":"2013","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.berh.2021.101691_bib88","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/art.38995","article-title":"Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis","volume":"67","author":"Belasco","year":"2015","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2021.101691_bib89","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ng.689","article-title":"Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2","volume":"42","author":"Ellinghaus","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.berh.2021.101691_bib90","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/ng.688","article-title":"Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis","volume":"42","author":"Huffmeier","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.berh.2021.101691_bib91","first-page":"1395823","article-title":"Influence of TNF and IL17 gene polymorphisms on the spondyloarthritis immunopathogenesis, regardless of HLA-B27, in a Brazilian population","author":"Rocha Loures","year":"2018","journal-title":"Mediat Inflamm"},{"key":"10.1016\/j.berh.2021.101691_bib92","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2018-214158","article-title":"Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis","volume":"78","author":"Aterido","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101691_bib93","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.rdc.2015.07.002","article-title":"Genetic, epigenetic and pharmacogenetic aspects of psoriasis and psoriatic arthritis","volume":"41","author":"O'Rielly","year":"2015","journal-title":"Rheum Dis Clin N Am"},{"key":"10.1016\/j.berh.2021.101691_bib94","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrg2884","article-title":"Analysing biological pathways in genome-wide association studies","volume":"11","author":"Wang","year":"2010","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.berh.2021.101691_bib95","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1038\/s41467-018-06672-6","article-title":"Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients","volume":"9","author":"Patrick","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.berh.2021.101691_bib96","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ajhg.2012.03.012","article-title":"PSORS2 is due to mutations in CARD14","volume":"90","author":"Jordan","year":"2012","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.berh.2021.101691_bib97","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.ajhg.2012.03.013","article-title":"Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis","volume":"90","author":"Jordan","year":"2012","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.berh.2021.101691_bib98","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa1013068","article-title":"Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis","volume":"365","author":"Marrakchi","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2021.101691_bib99","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ajhg.2011.07.022","article-title":"Mutations in IL36RN\/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis","volume":"89","author":"Onoufriadis","year":"2011","journal-title":"Am J Hum Genet"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694221000334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694221000334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:20:59Z","timestamp":1761499259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694221000334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":99,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1521694221000334"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2021.101691","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and molecular significance of genetic loci associated with psoriatic arthritis","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2021.101691","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101691"}}